Silo Pharma Extends Alzheimer's Therapeutics Research Pact

Silo Pharma Inc SILO entered into an agreement with Columbia University under which Silo has been granted an extension for its option to license certain assets currently under development, including Alzheimer's disease and Stress-Induced Anxiety.
"The first steps of our research with Columbia have been positive and we're happy to extend this research and option pact to continue the progress of SPC-14 as an Alzheimer's therapeutic and SPC-15 for Stress Induced Anxiety disorders," said Eric Weisblum, CEO of Silo Pharma.
The extension to the agreement incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology (in Psychiatry) at Columbia University Irving Medical Center.
Denny and her team focus on the molecular mechanisms underlying learning and memory, including Alzheimer's disease.
Silo is currently conducting ongoing research studies and looks forward to sharing these results as data becomes available.
Price Action: SILO shares are trading higher by 0.68% at $5.04 on the last check Tuesday.